AbCellera Biologics Inc.
ABCL
$4.18
-$0.12-2.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.97% | -12.34% | 27.44% | -78.63% | -20.97% |
| Total Depreciation and Amortization | -81.44% | -2.38% | -298.70% | 416.87% | 424.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 152.37% | -11.07% | 72.78% | -174.20% | -247.64% |
| Change in Net Operating Assets | -109.10% | 138.78% | 957.56% | -180.04% | -129.14% |
| Cash from Operations | -8.14% | 72.30% | 59.21% | -27,147.17% | -250.56% |
| Capital Expenditure | 33.54% | 55.94% | -8.31% | 8.93% | 26.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -125.55% | -65.64% | 618.93% | 194.42% | 1,104.42% |
| Cash from Investing | -161.06% | -73.47% | 246.79% | 128.92% | 251.49% |
| Total Debt Issued | 94.25% | 103.85% | 17.28% | -52.71% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -11.33% | -- |
| Repurchase of Common Stock | -- | -- | -46.30% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,752.46% | 3.78% | 4.32% | 1.08% | -315.29% |
| Cash from Financing | -227.31% | 110.88% | 10.01% | -52.56% | 532.70% |
| Foreign Exchange rate Adjustments | 1,869.77% | 175.54% | -302.25% | 134.52% | -105.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -370.13% | 130.17% | 175.92% | -195.86% | 286.42% |